Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc Corporate Call Transcript

Jul 03, 2019 / 05:30PM GMT
Release Date Price: €5.9 (+19.92%)
Operator

Good morning. My name is Victor, and I'll be your conference operator for today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics conference call to announce the FDA accelerated approval of XPOVIO. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Mr. Chris Primiano, Karyopharm's Chief Business Officer and General Counsel. You may begin.

Christopher Brett Primiano
Karyopharm Therapeutics Inc. - Executive VP, Chief Business Officer, General Counsel & Secretary

Thank you, Victor, and thank you all for joining us on this very exciting occasion to discuss the FDA's accelerated approval of XPOVIO, also known as selinexor, for the treatment of adult patients with highly refractory multiple myeloma. This is Chris Primiano, and I'm joined today by Dr. Sharon Shacham, Founder, President, Chief Scientific Officer and Inventor of XPOVIO; Dr. Michael Kauffman, Chief Executive Officer; Mr. Perry Monaco, Senior Vice President of Sales; and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot